RU2018126519A3 - - Google Patents

Info

Publication number: RU2018126519A3
Authority: RU; Russia

Application number

RU2018126519A

Other versions

RU2018126519A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-30

Filing date

2016-12-29

Publication date

2020-09-08

2016-12-29 Application filed filed Critical

2020-01-30 Publication of RU2018126519A publication Critical patent/RU2018126519A/ru

2020-09-08 Publication of RU2018126519A3 publication Critical patent/RU2018126519A3/ru

2021-03-16 Application granted granted Critical

2021-03-16 Publication of RU2744860C2 publication Critical patent/RU2744860C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

RU2018126519A 2015-12-30 2016-12-29 Антитела и их конъюгаты RU2744860C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562273177P	2015-12-30	2015-12-30
US62/273,177		2015-12-30
PCT/US2016/069336 WO2017117464A1 (en)	2015-12-30	2016-12-29	Antibodies and conjugates thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2021103004A Division RU2843347C1 (ru)	2015-12-30	2021-02-09	Антитела и их конъюгаты

Publications (3)

Publication Number	Publication Date
RU2018126519A RU2018126519A (ru)	2020-01-30
RU2018126519A3 true RU2018126519A3 (ru)	2020-09-08
RU2744860C2 RU2744860C2 (ru)	2021-03-16

Family

ID=59225788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018126519A RU2744860C2 (ru)	2015-12-30	2016-12-29	Антитела и их конъюгаты

Country Status (14)

Country	Link
US (2)	US11066465B2 (ru)
EP (1)	EP3397276A4 (ru)
JP (3)	JP7088454B2 (ru)
KR (2)	KR102799807B1 (ru)
CN (1)	CN108712911A (ru)
AU (2)	AU2016381964B2 (ru)
BR (1)	BR112018013407A2 (ru)
CA (1)	CA3010056A1 (ru)
IL (2)	IL290457B2 (ru)
MX (1)	MX2022014125A (ru)
NZ (2)	NZ783685A (ru)
RU (1)	RU2744860C2 (ru)
SG (1)	SG11201805420SA (ru)
WO (1)	WO2017117464A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011075185A1 (en)	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
EP3549963B1 (en) *	2010-04-15	2022-01-12	Kodiak Sciences Inc.	High molecular weight zwitterion-containing polymers
ES2819217T3 (es)	2013-09-08	2021-04-15	Kodiak Sciences Inc	Conjugados de polímeros iónicos dipolares y factor VIII
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
WO2016061562A2 (en)	2014-10-17	2016-04-21	Kodiak Sciences Inc.	Butyrylcholinesterase zwitterionic polymer conjugates
US11066465B2 (en)	2015-12-30	2021-07-20	Kodiak Sciences Inc.	Antibodies and conjugates thereof
WO2018191548A2 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
KR20200090927A (ko) *	2017-12-19	2020-07-29	아카우오스, 인크.	내이에 대한 치료적 항체의 aav-매개 전달
CN110003328B (zh) *	2018-01-05	2022-04-19	百奥泰生物制药股份有限公司	一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
MX2020009152A (es)	2018-03-02	2020-11-09	Kodiak Sciences Inc	Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
JP7345782B2 (ja) *	2018-07-31	2023-09-19	積水化学工業株式会社	検査方法、検査用器具及び検査装置
CA3113069A1 (en)	2018-09-17	2020-03-26	Abcuro, Inc.	Anti-klrg1 antibodies
CN113423730B (zh)	2019-02-15	2024-01-05	上海药明合联生物技术有限公司	用于制备具有改善的同质性的抗体-药物缀合物的方法
US12109273B2 (en)	2019-02-15	2024-10-08	Wuxi Xdc Singapore Private Limited	Process for preparing antibody-drug conjugates with improved homogeneity
WO2021023117A1 (zh) *	2019-08-02	2021-02-11	康方药业有限公司	抗ctla4-抗pd-1双特异性抗体及其用途
EP4041312A4 (en) *	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
WO2021104302A1 (zh) *	2019-11-25	2021-06-03	中山康方生物医药有限公司	抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途
BR112022018847A2 (pt) *	2020-03-24	2022-11-22	Genentech Inc	Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo
KR20230004726A (ko) *	2020-04-22	2023-01-06	아케소 바이오파마, 인크.	항-cd73/항-pd-1 이중특이항체 및 이의 용도
KR20220029343A (ko)	2020-08-31	2022-03-08	(주)메디톡스	항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
US20240067711A1 (en)	2020-08-31	2024-02-29	Medytox Inc.	Anti-vegf hexameric antibody and composition comprising same
CR20230228A (es)	2020-12-01	2023-07-18	Akouos Inc	Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
EP4323399A4 (en)	2021-04-14	2025-04-09	Kodiak Sciences Inc.	Methods of treating an eye disorder
JP2025505696A (ja) *	2022-02-10	2025-02-28	コディアックサイエンシーズインコーポレイテッド	生産物の精製方法
WO2024182318A2 (en) *	2023-02-28	2024-09-06	Kodiak Sciences Inc.	Antibodies to htra1 and conjugates thereof
WO2024254281A2 (en) *	2023-06-07	2024-12-12	Kodiak Sciences Inc.	Compositions of conjugated and unconjugated proteins
WO2024254282A2 (en) *	2023-06-07	2024-12-12	Kodiak Sciences Inc.	Methods for analyzing mixed compositions of protein and protein conjugates
CN117257977A (zh) *	2023-11-07	2023-12-22	正大天晴药业集团南京顺欣制药有限公司	用于制备抗体药物偶联物的方法

Family Cites Families (687)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
DE2023169C2 (de)	1970-05-12	1982-07-22	Hannes 8100 Garmisch-Partenkirchen Marker	Sicherheitsskibindung
JPS5296363A (en)	1976-02-06	1977-08-12	Takamatsu Electric Works Ltd	Device for supplementing gas in gas sealed distributing device
JPS5472168A (en)	1977-11-18	1979-06-09	Tiger Vacuum Bottle Ind	Electric cooking implement
JPS5846044B2 (ja)	1979-04-14	1983-10-14	日本金属株式会社	圧粉鉄心
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
CH652145A5 (de)	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4609707A (en)	1983-11-10	1986-09-02	Genetic Systems Corporation	Synthesis of polymers containing integral antibodies
US4634666A (en)	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
SE447704B (sv)	1985-04-16	1986-12-08	Flaekt Ab	Anordning vid kontaktreaktor innefattande medel att forhindra atercirkulation av absorptionsmaterial till dysans yta
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
PT88641B (pt)	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en)	1987-11-17	1994-02-01	Brown University Research Foundation	Cell culture-containing tubular capsule produced by co-extrusion
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US5252713A (en)	1988-09-23	1993-10-12	Neorx Corporation	Polymeric carriers for non-covalent drug conjugation
US5047335A (en)	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1990007936A1 (en)	1989-01-23	1990-07-26	Chiron Corporation	Recombinant therapies for infection and hyperproliferative disorders
FI914427A0 (fi)	1989-03-21	1991-09-20	Vical Inc	Expression av exogena polynukleotid- sekvenser i ett ryggradsdjur.
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP1645635A3 (en)	1989-08-18	2010-07-07	Oxford Biomedica (UK) Limited	Replication defective recombinant retroviruses expressing a palliative
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
NZ237464A (en)	1990-03-21	1995-02-24	Depotech Corp	Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en)	1990-08-29	2007-04-03	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0584082T3 (da)	1991-01-31	2000-10-16	Univ California	Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
US5278299A (en)	1991-03-18	1994-01-11	Scripps Clinic And Research Foundation	Method and composition for synthesizing sialylated glycosyl compounds
DE4110409C2 (de)	1991-03-29	1999-05-27	Boehringer Ingelheim Int	Neue Protein-Polykation-Konjugate
US5325525A (en)	1991-04-04	1994-06-28	Hewlett-Packard Company	Method of automatically controlling the allocation of resources of a parallel processor computer system by calculating a minimum execution time of a task and scheduling subtasks against resources to execute the task in the minimum time
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
AU663725B2 (en)	1991-08-20	1995-10-19	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Adenovirus mediated transfer of genes to the gastrointestinal tract
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vectors including foreign genes and negative selective markers
AU3144193A (en)	1991-11-21	1993-06-15	Board Of Trustees Of The Leland Stanford Junior University	Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en)	1991-12-02	1992-01-29	Dynal As	Cell modification
US5817310A (en)	1991-12-02	1998-10-06	Cor Therapeutics, Inc.	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
FR2688514A1 (fr)	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1993025673A1 (en)	1992-06-04	1993-12-23	The Regents Of The University Of California	In vivo gene therapy with intron-free sequence of interest
JPH07507689A (ja)	1992-06-08	1995-08-31	ザリージェンツオブザユニバーシティオブカリフォルニア	特定組織のターゲティング方法及び組成物
JPH09507741A (ja)	1992-06-10	1997-08-12	アメリカ合衆国	ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
CA2145641C (en)	1992-12-03	2008-05-27	Richard J. Gregory	Pseudo-adenovirus vectors
CA2150262C (en)	1992-12-04	2008-07-08	Kaspar-Philipp Holliger	Multivalent and multispecific binding proteins, their manufacture and use
GB9301702D0 (en)	1993-01-28	1993-03-17	Biocompatibles Ltd	New materials
ATE281469T1 (de)	1993-03-25	2004-11-15	Merck & Co Inc	Inhibitor des wachstumsfaktors für gefäss- endothelzellen
EP0695169B1 (en)	1993-04-22	2002-11-20	SkyePharma Inc.	Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DE69434486T2 (de)	1993-06-24	2006-07-06	Advec Inc.	Adenovirus vektoren für gentherapie
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
EP0814154B1 (en)	1993-09-15	2009-07-29	Novartis Vaccines and Diagnostics, Inc.	Recombinant alphavirus vectors
ATE437232T1 (de)	1993-10-25	2009-08-15	Canji Inc	Rekombinanter adenoviren-vektor und verfahren zur verwendung
NZ276305A (en)	1993-11-16	1997-10-24	Depotech Corp	Controlled release vesicle compositions
GB9324033D0 (en)	1993-11-23	1994-01-12	Biocompatibles Ltd	Ethylenically unsaturated compounds
US5914349A (en)	1994-01-10	1999-06-22	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US6436908B1 (en)	1995-05-30	2002-08-20	Duke University	Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ES2297831T3 (es)	1994-05-09	2008-05-01	Oxford Biomedica (Uk) Limited	Vectores retroviricos que presentan una tasa de recombinacion reducida.
AU4594996A (en)	1994-11-30	1996-06-19	Chiron Viagene, Inc.	Recombinant alphavirus vectors
US5681746A (en)	1994-12-30	1997-10-28	Chiron Viagene, Inc.	Retroviral delivery of full length factor VIII
US5763548A (en)	1995-03-31	1998-06-09	Carnegie-Mellon University	(Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
US6541580B1 (en)	1995-03-31	2003-04-01	Carnegie Mellon University	Atom or group transfer radical polymerization
JPH09154588A (ja)	1995-10-07	1997-06-17	Toagosei Co Ltd	Ｖｅｇｆ結合性ポリペプチド
EP0863908A1 (en)	1995-10-16	1998-09-16	Biocompatibles Limited	Oxidation of phosphorus compounds
GB9521234D0 (en)	1995-10-16	1995-12-20	Biocompatibles Ltd	Synthesis of polymerisable phospho diesters
US5807937A (en)	1995-11-15	1998-09-15	Carnegie Mellon University	Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties
US5663425A (en)	1996-01-26	1997-09-02	Lignotech Usa, Inc.	Production of acid soluble humates
US6441025B2 (en)	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
US5882644A (en)	1996-03-22	1999-03-16	Protein Design Labs, Inc.	Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
EP0953052B1 (en)	1996-05-06	2009-03-04	Oxford BioMedica (UK) Limited	Crossless retroviral vectors
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5789487A (en)	1996-07-10	1998-08-04	Carnegie-Mellon University	Preparation of novel homo- and copolymers using atom transfer radical polymerization
US5863551A (en)	1996-10-16	1999-01-26	Organogel Canada Ltee	Implantable polymer hydrogel for therapeutic uses
JPH10139832A (ja)	1996-11-08	1998-05-26	Nof Corp	共重合体およびグルコースセンサー
US7122636B1 (en)	1997-02-21	2006-10-17	Genentech, Inc.	Antibody fragment-polymer conjugates and uses of same
WO1998037200A2 (en)	1997-02-21	1998-08-27	Genentech, Inc.	Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US7125938B2 (en)	1997-03-11	2006-10-24	Carnegie Mellon University	Atom or group transfer radical polymerization
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
US20150023951A1 (en)	1997-04-07	2015-01-22	Genentech, Inc.	Anti-vegf antibodies
EP1787999B1 (en)	1997-04-07	2010-08-04	Genentech, Inc.	Anti-VEGF antibodies
EP2338915A3 (en)	1997-04-07	2011-10-12	Genentech, Inc.	Anti-VEGF antibodies
JP3052923B2 (ja)	1997-05-30	2000-06-19	日本油脂株式会社	（メタ）アクリレート誘導体の製造方法
US6376471B1 (en)	1997-10-10	2002-04-23	Johns Hopkins University	Gene delivery compositions and methods
US8088386B2 (en)	1998-03-20	2012-01-03	Genentech, Inc.	Treatment of complement-associated disorders
US8007798B2 (en)	1997-11-21	2011-08-30	Genentech, Inc.	Treatment of complement-associated disorders
JP2002502056A (ja)	1998-01-30	2002-01-22	ファースト・ケミカル・コーポレイション	マレイミドを含む光重合組成物およびその使用方法
JP4162284B2 (ja)	1998-02-04	2008-10-08	日油株式会社	洗浄剤組成物
CA2321140C (en)	1998-02-20	2015-04-07	Tanox, Inc.	Inhibitors of complement activation
US6121371A (en)	1998-07-31	2000-09-19	Carnegie Mellon University	Application of atom transfer radical polymerization to water-borne polymerization systems
GB9812550D0 (en)	1998-06-11	1998-08-05	Aepact Ltd	Tumour therapy and imaging
WO2000009560A2 (en)	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
EP1135498B1 (en)	1998-11-18	2008-01-23	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
WO2000034337A1 (en)	1998-12-10	2000-06-15	Tsukuba Research Laboratory, Toagosei Co., Ltd.	Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6344050B1 (en)	1998-12-21	2002-02-05	Light Sciences Corporation	Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
EP1140173B2 (en)	1998-12-22	2013-04-03	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
CN100489892C (zh)	1999-02-05	2009-05-20	三星电子株式会社	恢复描述图像的纹理特征的图像纹理描述符的方法及装置
US6384146B1 (en)	1999-04-05	2002-05-07	The Research Foundation Of State University Of New York	Graft, graft-block, block-graft, and star-shaped copolymers and methods of making them
ATE269357T1 (de)	1999-04-28	2004-07-15	Univ Texas	Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
US7306799B2 (en)	1999-06-08	2007-12-11	Regeneron Pharmaceuticals, Inc.	Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en)	1999-06-08	2008-07-08	Regeneron Pharmaceuticals, Inc.	VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en)	1999-06-08	2004-12-21	Regeneron Pharmaceuticals, Inc.	Methods of treating inflammatory skin diseases
GB9914650D0 (en)	1999-06-24	1999-08-25	Angyogene Pharmaceuticals Ltd	Chimeric proteins mediating targeted apoptosis
CZ299516B6 (cs)	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
ATE407697T1 (de)	1999-07-13	2008-09-15	Bolder Biotechnology Inc	Erythropoietin immunglobulin fusionsproteine
US7049373B2 (en)	1999-08-06	2006-05-23	Carnegie Mellon University	Process for preparation of graft polymers
DE60020864T2 (de)	1999-09-08	2006-04-27	Polytherics Ltd.	Polymere mit uniformem molekulargewicht
GB9928956D0 (en)	1999-12-07	2000-02-02	Malik Navid	Internally supported biomimetic coating systems
DK2042597T3 (da)	2000-06-23	2014-08-11	Genentech Inc	Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
US20020091082A1 (en)	2000-09-13	2002-07-11	Aiello Lloyd P.	Methods of modulating symptoms of hypertension
WO2002028914A2 (en)	2000-10-06	2002-04-11	Carnegie Mellon University	A catalyst system for controlled polymerization
US6627314B2 (en)	2000-10-06	2003-09-30	Carnegie Mellon University	Preparation of nanocomposite structures by controlled polymerization
WO2002028913A2 (en)	2000-10-06	2002-04-11	Carnegie Mellon University	Polymerization process for ionic monomers
DE60129148T2 (de)	2000-10-06	2008-02-28	Biocompatibles Uk Ltd., Farnham	Zwitterionische polymere
US6979556B2 (en) *	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
ATE470647T1 (de)	2001-04-06	2010-06-15	Univ Carnegie Mellon	Verfahren zur herstellung von nanostrukturierten materialien
US20040010376A1 (en)	2001-04-17	2004-01-15	Peizhi Luo	Generation and selection of protein library in silico
CN1671416B (zh)	2001-07-12	2013-01-02	杰斐逊·富特	超人源化抗体
WO2003021253A2 (de)	2001-08-27	2003-03-13	Zeptosens Ag	Bionalytische erkennungsoberfläche mit optimierter dichte der erkennungselemente
JP2003064132A (ja)	2001-08-28	2003-03-05	Nof Corp	重合体、製造方法および乳化・分散剤
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
AU2002339863A1 (en)	2001-08-31	2003-03-18	Abmaxis, Inc.	Multivalent protein conjugate with multiple ligand-binding domains of receptors
US7064166B2 (en)	2001-10-12	2006-06-20	Carnegie Mellon University	Process for monomer sequence control in polymerizations
US6759491B2 (en)	2001-10-12	2004-07-06	Carnegie Mellon University	Simultaneous reverse and normal initiation of ATRP
WO2003040211A2 (en)	2001-11-07	2003-05-15	Nektar Therapeutics Al, Corporation	Branched polymers and their conjugates
WO2003039404A2 (en)	2001-11-09	2003-05-15	Eyetech Pharmaceuticals	Methods for treating ocular neovascular diseases
DK2308888T3 (en)	2001-11-14	2017-06-06	Janssen Biotech Inc	Anti-IL-6 Antibodies, Compositions, Methods and Uses
CU23225A1 (es)	2001-12-20	2007-08-30	Ct Ingenieria Genetica Biotech	PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
US8048408B2 (en)	2002-01-16	2011-11-01	Biocompatibles Uk Limited	Polymer conjugates
GB0202494D0 (en)	2002-02-02	2002-03-20	Avecia Ltd	Process
US6992176B2 (en)	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050220880A1 (en)	2002-03-07	2005-10-06	Lewis Andrew L	Drug carriers comprising amphiphilic block copolymers
US8182802B2 (en)	2002-03-07	2012-05-22	Biocompatibles Uk Limited	Composition of polymers
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CA2479212A1 (en)	2002-03-15	2003-09-25	Brigham And Women's Hospital, Inc.	Central airway administration for systemic delivery of therapeutics
AU2003225910A1 (en)	2002-03-20	2003-10-08	Johns Hopkins University	Raav vector compositions and methods for the treatment of choroidal neovascularization
JP4248189B2 (ja)	2002-04-09	2009-04-02	株式会社資生堂	ホスホリルコリン基含有多糖類及びその製造方法
AU2003241531A1 (en)	2002-05-21	2003-12-12	Emory University	Multivalent polymers with chain-terminating binding groups
CA2490280A1 (en)	2002-07-01	2004-01-08	Human Genome Sciences, Inc.	Antibodies that specifically bind to reg iv
US7148342B2 (en)	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
US7019082B2 (en)	2002-08-09	2006-03-28	Carnegie Mellon University	Polymers, supersoft elastomers and methods for preparing the same
WO2004019860A2 (en)	2002-08-28	2004-03-11	Pharmacia Corporation	Formulations of modified antibodies and methods of making the same
WO2004019861A2 (en)	2002-08-28	2004-03-11	Pharmacia Corporation	Stable ph optimized formulation of a modified antibody
DK1539157T3 (da)	2002-09-18	2013-10-07	Univ Pennsylvania	Fremgangsmåde til hæmning af choroidal neovaskularisering
US20060165804A1 (en)	2002-09-25	2006-07-27	Lewis Andrew L	Polymer compositions for administration to animals
AU2003292304A1 (en)	2002-11-07	2004-06-03	Rhodia Chimie	Controlled structure copolymer comprising an amphoteric or zwitterionic part
US20070111279A1 (en)	2002-11-13	2007-05-17	Procell, Inc.	Production of recombinant therapeutic bioscavengers against chemical and biological agents
GB0228409D0 (en)	2002-12-06	2003-01-08	Thromb X Nv	Pharmacological vitreolysis
GB0301014D0 (en)	2003-01-16	2003-02-19	Biocompatibles Ltd	Conjugation reactions
US20060167230A1 (en)	2003-01-20	2006-07-27	Takaki Koga	Anti-pci neutralizing antibody
EP1585768A2 (en) *	2003-01-23	2005-10-19	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
TR201808801T4 (tr)	2003-02-10	2018-07-23	Biogen Ma Inc	İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi.
CA2530166A1 (en)	2003-03-07	2004-09-23	Randolph D. Glickman	Antibody-targeted photodynamic therapy
US7052691B2 (en)	2003-03-28	2006-05-30	Regeneron Pharmaceuticals, Inc.	Methods of treating diabetes by blocking VEGF-mediated activity
US20120183593A1 (en)	2003-04-09	2012-07-19	Directcontact Llc	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en)	2003-04-09	2005-04-07	Schultz Clyde L.	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2004091494A2 (en)	2003-04-11	2004-10-28	Pr Pharmaceuticals Inc.	Method for preparation of site-specific protein conjugates
US20040266688A1 (en)	2003-05-14	2004-12-30	Nayak Nihar R	Methods for modulating endometrium
JP2007525187A (ja)	2003-05-16	2007-09-06	レセプター・バイオロジクス・インコーポレイテッド	イントロン融合タンパク質、ならびにその同定方法および使用方法
MXPA05008973A (es)	2003-05-28	2006-02-22	Regeneron Pharma	Metodo de tratamiento de rechazo de trasplante de cornea.
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2004110490A2 (en)	2003-06-06	2004-12-23	Regeneron Pharmaceuticals, Inc.	Use of vegf inhibitors for tumor regression
GB0314472D0 (en)	2003-06-20	2003-07-23	Warwick Effect Polymers Ltd	Polymer
AR046510A1 (es)	2003-07-25	2005-12-14	Regeneron Pharma	Composicion de un antagonista de vegf y un agente anti-proliferativo
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
AU2004263681A1 (en)	2003-08-04	2005-02-17	Laboratoires Serono Sa	Novel therapeutic fusion proteins
US20050112061A1 (en)	2003-08-06	2005-05-26	Jocelyn Holash	Use of a VEGF antagonist in combination with radiation therapy
AU2004268614C1 (en)	2003-08-27	2010-10-28	Ophthotech Corporation	Combination therapy for the treatment of ocular neovascular disorders
HRP20171094T1 (hr)	2003-09-17	2017-10-06	Nektar Therapeutics	Višestruko razgranati polimerni prolijekovi
JP2005141865A (ja)	2003-11-07	2005-06-02	Toyota Motor Corp	高密度記録媒体
US20050100550A1 (en)	2003-11-10	2005-05-12	Mohit Trikha	Anti-angiogenic uses of IL-6 antagonists
KR100775343B1 (ko)	2003-11-13	2007-11-08	한미약품 주식회사	면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
NZ594834A (en)	2003-12-16	2013-03-28	Nektar Therapeutics	Method of preparing PEGylated protein molecules
US8298532B2 (en)	2004-01-16	2012-10-30	Regeneron Pharmaceuticals, Inc.	Fusion polypeptides capable of activating receptors
US7127655B2 (en)	2004-01-20	2006-10-24	Qualcomm, Inc.	Methods and apparatus to optimize delivery of multicast content using probabilistic feedback
EP1708752B1 (en)	2004-01-27	2012-02-22	University Of Southern California	Polymer-bound antibody cancer therapeutic agent
KR100593443B1 (ko)	2004-02-11	2006-06-28	삼성전자주식회사	트랜지스터들 및 그 제조방법들
JP4727938B2 (ja)	2004-02-24	2011-07-20	泰彦岩崎	リビングラジカル重合開始基を持つポリリン酸の製造方法および用途
ATE507240T1 (de)	2004-03-05	2011-05-15	Vegenics Pty Ltd	Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20050282233A1 (en)	2004-03-05	2005-12-22	Ludwig Institute For Cancer Research	Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
JP4727941B2 (ja)	2004-03-12	2011-07-20	泰彦岩崎	生分解性重合体の製造方法および用途
US20050208093A1 (en)	2004-03-22	2005-09-22	Thierry Glauser	Phosphoryl choline coating compositions
US20070059336A1 (en)	2004-04-30	2007-03-15	Allergan, Inc.	Anti-angiogenic sustained release intraocular implants and related methods
US20050244472A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en)	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
US20050244469A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Extended therapeutic effect ocular implant treatments
KR100897379B1 (ko)	2004-06-08	2009-05-14	쳉두 캉홍 바이오테크놀로지스 코. 리미티드	혈관신생-저해 키메릭 단백질 및 그 사용
EP1763365B1 (en)	2004-06-09	2016-08-10	Technion Research And Development Foundation, Ltd.	Antibodies for selective apoptosis of cells
WO2005123104A2 (en)	2004-06-10	2005-12-29	Regeneron Pharmaceuticals, Inc.	Use of vegf inhibitors for the treatment of human cancer
US7863238B2 (en)	2004-06-10	2011-01-04	Saint Louis University	Proteins with an attached short peptide of acidic amino acids
US20050281822A1 (en)	2004-06-18	2005-12-22	Cedarbaum Jesse M	Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
WO2006019851A1 (en)	2004-07-23	2006-02-23	Eli Lilly And Company	Methods for diagnosing and treating diabetic microvascular complications
JP4807802B2 (ja)	2004-07-30	2011-11-02	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｖｅｇｆ媒介性活性をブロックすることによるｉ型糖尿病を処置する方法
DK2319925T3 (da)	2004-08-16	2018-11-05	Quark Pharmaceuticals Inc	Terapeutiske anvendelser af RTP801-hæmmere
AU2005285347A1 (en)	2004-08-19	2006-03-23	Genentech, Inc.	Polypeptide variants with altered effector function
WO2006031689A2 (en)	2004-09-13	2006-03-23	Genzyme Corporation	Multimeric constructs
ES2579805T3 (es)	2004-09-23	2016-08-16	Genentech, Inc.	Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AU2005289415A1 (en)	2004-09-24	2006-04-06	Rfe Pharma Llc	Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20080292628A1 (en)	2004-10-12	2008-11-27	Amprotein Corporation	Chimeric Protein
WO2006047325A1 (en)	2004-10-21	2006-05-04	Genentech, Inc.	Method for treating intraocular neovascular diseases
US8048418B2 (en)	2004-10-29	2011-11-01	Regeneron Pharmaceuticals, Inc.	Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7214759B2 (en)	2004-11-24	2007-05-08	Advanced Cardiovascular Systems, Inc.	Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
FR2878749B1 (fr)	2004-12-03	2007-12-21	Aventis Pharma Sa	Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
WO2006063055A2 (en)	2004-12-06	2006-06-15	Bolder Biotechnology, Inc.	Enzyme conjugates for use as detoxifying agents
AR051800A1 (es)	2004-12-15	2007-02-07	Wyeth Corp	Anticuerpos a beta usados en mejorar la cognicion
WO2006081311A2 (en)	2005-01-26	2006-08-03	Medical College Of Georgia Research Institute	Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors
WO2006084054A2 (en)	2005-02-02	2006-08-10	Children's Medical Center Corporation	Method of treating angiogenic diseases
WO2006088650A2 (en)	2005-02-02	2006-08-24	Regeneron Pharmaceuticals, Inc.	Method of treating eye injury with local administration of a vegf inhibitor
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
WO2006086544A2 (en)	2005-02-11	2006-08-17	Regeneron Pharmaceuticals, Inc.	Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
US7803375B2 (en)	2005-02-23	2010-09-28	Massachusetts Eye And Ear Infirmary	Methods and compositions for treating conditions of the eye
PL2289533T3 (pl)	2005-02-28	2014-02-28	Oncotherapy Science Inc	Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
JP5241484B2 (ja)	2005-03-07	2013-07-17	ザユニヴァーシティーオヴシカゴ	内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
EP1863931A2 (en)	2005-03-07	2007-12-12	The Trustees Of Boston University	Diagnostic and therapeutic target for macular degeneration
US20090117103A1 (en)	2005-03-08	2009-05-07	Pharmacia & Upjohn Company Llc	M-CSF Antibody compositions Having Reduced Levels of Endotoxin
EP1855708A1 (en)	2005-03-11	2007-11-21	Regeneron Pharmaceuticals, Inc.	Treating anemia by inhibition of vegf
DK1861116T3 (en)	2005-03-25	2015-11-09	Regeneron Pharma	VEGF antagonist formulations
US20060234347A1 (en)	2005-04-13	2006-10-19	Harding Thomas C	Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
JP5541861B2 (ja)	2005-04-29	2014-07-09	エージェンシーフォーサイエンス，テクノロジーアンドリサーチ	超分岐ポリマーおよびそれらの適用
PE20061324A1 (es)	2005-04-29	2007-01-15	Centocor Inc	Anticuerpos anti-il-6, composiciones, metodos y usos
US20070005130A1 (en)	2005-06-29	2007-01-04	Thierry Glauser	Biodegradable polymer for coating
WO2007011873A2 (en)	2005-07-15	2007-01-25	Genentech, Inc.	Method for treating intraocular neovascular diseases
WO2008020827A2 (en)	2005-08-01	2008-02-21	Biogen Idec Ma Inc.	Altered polypeptides, immunoconjugates thereof, and methods related thereto
EP1928470A4 (en)	2005-08-02	2010-09-15	Bionaut Pharmaceuticals Inc	HYPOXIC INDUCIBLE FACTOR-1 MODULATORS AND RELEVANT APPLICATIONS FOR THE TREATMENT OF EYE DISEASES
RU2414924C2 (ru)	2005-08-12	2011-03-27	Ридженерон Фармасьютикалз, Инк.	Способы лечения заболеваний антагонистами vegf
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
EP1928907A4 (en)	2005-08-15	2009-03-11	Univ California	VEGF-ACTIVATED FAS LIGANDS
WO2007022416A2 (en)	2005-08-18	2007-02-22	Ramot At Tel Aviv University Ltd.	Single chain antibodies against beta-amyloid peptide
EP1943278B1 (en)	2005-08-26	2010-10-06	Carnegie Mellon University	Polymerization process with catalyst reactivation
US20070071756A1 (en)	2005-09-26	2007-03-29	Peyman Gholam A	Delivery of an agent to ameliorate inflammation
US20080167600A1 (en)	2005-09-26	2008-07-10	Peyman Gholam A	Device for delivery of an agent to the eye and other sites
WO2007041614A2 (en)	2005-10-03	2007-04-12	Bolder Biotechnology, Inc.	Long acting vegf inhibitors and methods of use
US20070134244A1 (en)	2005-10-14	2007-06-14	Alcon, Inc.	Combination treatment for pathologic ocular angiogenesis
AU2006320535B2 (en)	2005-11-29	2010-09-23	Glaxosmithkline Llc	Treatment method
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
BRPI0620080A2 (pt)	2005-12-19	2011-11-01	Comentis Inc	formulações tópicas de mecamilamina para adminstração ocular e usos das mesma
US7906134B2 (en)	2005-12-21	2011-03-15	Abbott Laboratories	Room temperature-curable polymers
US20090098139A1 (en)	2006-01-30	2009-04-16	Barrett Katz	Combination therapy for the treatment of neovascular disorders
WO2007097839A2 (en)	2006-02-16	2007-08-30	Massachusetts Eye And Ear Infirmary	Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
DE102006009004A1 (de)	2006-02-23	2007-09-06	Sustech Gmbh & Co. Kg	Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung
PT1988910T (pt)	2006-02-28	2018-02-07	Kodiak Sciences Inc	Acriloiloxietilfosforilcolina contendo conjugados de polímeros e sua preparação
SI2596807T1 (sl)	2006-03-08	2016-03-31	Archemix Llc	Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
US7354582B2 (en)	2006-03-10	2008-04-08	Regeneron Pharmaceuticals, Inc.	Use of VEGF antagonists for the treatment of malignant gliomas
KR20080103562A (ko) *	2006-03-15	2008-11-27	말린크로트, 인코포레이티드	치환된 방향족 잔기 및 그의 유도체를 갖는 킬레이팅 컨쥬게이트
EP2012751A4 (en)	2006-03-21	2010-11-24	Morehouse School Of Medicine	NEW NANOPARTICLES FOR THE DELIVERY OF ACTIVE AGENTS
PL1989231T3 (pl)	2006-03-21	2015-10-30	Genentech Inc	Terapia kombinatoryczna z udziałem antagonistów alfa5beta1
JP2007263935A (ja)	2006-03-30	2007-10-11	Canon Inc	磁性マーカー及びその製造方法
US8216575B2 (en)	2006-03-31	2012-07-10	Chengdu Kanghong Biotechnologies Co., Ltd.	Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
GB0620255D0 (en)	2006-10-12	2006-11-22	Fusion Antibodies Ltd	Antibody and uses thereof
JP2009533519A (ja)	2006-04-14	2009-09-17	インターフェースバイオロジクス，インコーポレーテッド	グラフトポリマーおよびその使用
US20070258976A1 (en)	2006-05-04	2007-11-08	Ward Keith W	Combination Therapy for Diseases Involving Angiogenesis
EP2012826B1 (en)	2006-05-04	2016-04-13	Fovea Pharmaceuticals	Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
EP2383341A1 (en)	2006-06-12	2011-11-02	Exegenics, Inc., D/b/a Opko Health, Inc.	Compositions and methods for siRNA inhibition of angiogenesis
PT2944306T (pt)	2006-06-16	2021-02-15	Regeneron Pharma	Formulações antagonistas de vegf adequadas para administração intravitreal
EP2230264B1 (en)	2006-06-29	2019-10-09	Life Technologies AS	Particles containing multi-block polymers
US20080008736A1 (en)	2006-07-06	2008-01-10	Thierry Glauser	Random copolymers of methacrylates and acrylates
WO2008006912A2 (en)	2006-07-14	2008-01-17	Biocompatibles Uk Limited	Polymer
KR100808116B1 (ko)	2006-08-22	2008-03-03	전남대학교산학협력단	미생물 점착 방지용 공중합체 수지 코팅재
US20100056428A1 (en)	2006-09-01	2010-03-04	Novo Nordisk Health Care Ag	Modified proteins
US20080070855A1 (en)	2006-09-20	2008-03-20	James Pitzer Gills	Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
CN102006885A (zh)	2006-10-20	2011-04-06	先灵公司	完全人源抗vegf抗体及其使用方法
JP5111016B2 (ja)	2006-11-01	2012-12-26	三井化学株式会社	表面親水性ポリオレフィン成形体およびその製造方法
CU23636A1 (es)	2006-11-01	2011-03-21	Ct Ingenieria Genetica Biotech	Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
BRPI0716299A2 (pt)	2006-11-02	2013-08-13	Genentech Inc	anticorpos murino,anticorpo quimÉrico, domÍnios variÁveis de um anticorpo humanizado, anticorpos anti-fator d humanizado, polipeptÍdeos, anticorpo humanizado, fragmento de anticorpo, Ácidos nuclÉico isolados, vetores , linhagem celular, composiÇço, uso, mÉtodo para produÇço de um anticorpo anti-fator d humanizado ou fragmentos destes e anticorpos
US8039010B2 (en)	2006-11-03	2011-10-18	Allergan, Inc.	Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
AU2007323925A1 (en)	2006-11-10	2008-05-29	Genentech, Inc.	Method for treating age-related macular degeneration
US20080118500A1 (en)	2006-11-16	2008-05-22	Taiwan Liposome Company	Sustained releasing composition via local injection for treating eye diseases
WO2008064058A2 (en)	2006-11-21	2008-05-29	Abbott Laboratories	Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings
ES2523915T5 (es)	2006-12-01	2022-05-26	Seagen Inc	Agentes de unión a la diana variantes y usos de los mismos
WO2008070479A2 (en)	2006-12-01	2008-06-12	Allergan, Inc.	Method for determining optimum intraocular locations for drug delivery systems
BRPI0806313A2 (pt)	2007-01-09	2011-09-06	Wyeth Corp	Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida
RU2009132674A (ru)	2007-02-01	2011-03-10	Дженентек, Инк. (Us)	Комбинированная терапия с использованием ингибиторов ангиогенеза
WO2008098930A1 (en)	2007-02-14	2008-08-21	Biocompatibes Uk Limited	Derivatisation of biological molecules
WO2008098299A1 (en)	2007-02-14	2008-08-21	Opto Global Holdings Pty Ltd	Methods and systems of treating age-related macular degeneration
US10259860B2 (en)	2007-02-27	2019-04-16	Aprogen Inc.	Fusion proteins binding to VEGF and angiopoietin
CN101631568B (zh)	2007-03-12	2012-08-22	尼克塔治疗公司	低聚物-蛋白酶抑制剂偶联物
EP2121031B1 (en)	2007-03-12	2013-10-16	Nektar Therapeutics	Oligomer-antihistamine conjugates
BRPI0809594A2 (pt)	2007-04-03	2019-08-27	Micromet Ag	polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
NZ580755A (en)	2007-04-03	2012-05-25	Micromet Ag	Cross-species-specific cd3-epsilon binding domain
EA019595B1 (ru)	2007-04-17	2014-04-30	Имклоун Элэлси	СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
US8003097B2 (en) *	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
WO2008137159A1 (en)	2007-05-07	2008-11-13	Gammacan	Human anti-vegf polyclonal antibodies and uses thereof
AR066476A1 (es) *	2007-05-08	2009-08-19	Genentech Inc	Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
EP2152293B1 (en)	2007-05-11	2016-10-19	The Board of Regents of the University of Nebraska	Compositions for protein delivery and methods of use thereof
WO2008144248A1 (en)	2007-05-14	2008-11-27	Tyco Healthcare Group Lp	Furanone copolymers
AU2008262489B2 (en)	2007-05-23	2013-11-28	Ventana Medical Systems, Inc.	Polymeric carriers for immunohistochemistry and in situ hybridization
CA2683791A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, antibody variable domains & antagonists
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
DK2173890T3 (da)	2007-06-21	2011-06-27	Univ Muenchen Tech	Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
KR102262298B1 (ko)	2007-07-09	2021-06-07	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
KR20160021307A (ko)	2007-07-10	2016-02-24	더 리전트 오브 더 유니버시티 오브 캘리포니아	선택된 조직에 조성물을 전달하는 물질 및 방법
JP2009042617A (ja)	2007-08-10	2009-02-26	Canon Inc	静電荷像現像用トナー及びその製造方法
AU2008289178A1 (en)	2007-08-16	2009-02-26	Carnegie Mellon University	Inflammation-regulating compositions and methods
US7943370B2 (en)	2007-08-23	2011-05-17	Canon Kabushiki Kaisha	Structure, target substance detection element and target substance detection kit
PE20091029A1 (es)	2007-09-26	2009-08-19	Genentech Inc	Anticuerpos anti-alfa 5 beta 1
US20090092664A1 (en)	2007-10-08	2009-04-09	University Of Kentucky Research Foundation	Polymer-metal chelator conjugates and uses thereof
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2209808B1 (en)	2007-10-19	2014-01-15	Genentech, Inc.	Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2009053368A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Single ifn-beta fused to a mutated igg fc fragment
US8216571B2 (en)	2007-10-22	2012-07-10	Schering Corporation	Fully human anti-VEGF antibodies and methods of using
AR070032A1 (es)	2007-11-09	2010-03-10	Genentech Inc	Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1)
KR101502267B1 (ko)	2007-11-09	2015-03-18	페레그린 파마수티컬즈, 인크	항-ｖｅｇｆ 항체 조성물 및 방법
GB0722484D0 (en)	2007-11-15	2007-12-27	Ucl Business Plc	Solid compositions
CN101878316B (zh)	2007-11-28	2012-09-19	新日本制铁株式会社	连续退火炉用炉底辊及其制造方法
US20110033378A1 (en) *	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
JP5343092B2 (ja) *	2008-01-29	2013-11-13	カリフォルニアインスティチュートオブテクノロジー	細胞分離を行う精密濾過の方法及び装置
RU2553566C2 (ru) *	2008-01-31	2015-06-20	Дженентек, Инк.	АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009105669A2 (en)	2008-02-20	2009-08-27	Genzyme Corporation	Angiogenesis inhibition
JP2011513229A (ja)	2008-02-21	2011-04-28	イスタ・ファーマスーティカルズ・インコーポレイテッド	補助剤としての眼科用ｎｓａｉｄ
US20090220434A1 (en)	2008-02-29	2009-09-03	Florida State University Research Foundation	Nanoparticles that facilitate imaging of biological tissue and methods of forming the same
JP2011512857A (ja)	2008-03-14	2011-04-28	インスティテュートナショナルデインベスティゲイションワイテクノロジアアグラリアワイアリメンタリア	抗原提示細胞へとワクチン抗原を向かわせることを伴う、融合タンパク質と、その応用
JP5823858B2 (ja)	2008-03-26	2015-11-25	エピトミクスインコーポレーティッド	抗ｖｅｇｆ抗体
JP5425180B2 (ja)	2008-03-27	2014-02-26	ザイモジェネティクス，インコーポレイテッド	ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
US20100260668A1 (en)	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
NZ588554A (en)	2008-04-29	2013-03-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US7740844B2 (en)	2008-04-29	2010-06-22	Taiwan Liposome Co. Ltd	Anti-VEGF monoclonal antibody
WO2009138473A2 (en)	2008-05-15	2009-11-19	Biocompatibles Uk Limited	Intracellular antibody delivery
CA2726087A1 (en)	2008-06-03	2009-12-10	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
WO2009149205A2 (en)	2008-06-03	2009-12-10	Neurotech Usa, Inc.	Cell lines that secrete soluble vegf receptors and uses thereof
WO2009155724A2 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	Stable and soluble antibodies inhibiting vegf
US8187623B2 (en)	2008-06-25	2012-05-29	Boston Scientific Scimed, Inc.	Medical copolymers
WO2010003101A2 (en)	2008-07-02	2010-01-07	Trubion Pharmaceuticals, Inc.	Il6 immunotherapeutics
US20110117189A1 (en)	2008-07-08	2011-05-19	S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A.	Ophthalmic compositions for treating pathologies of the posterior segment of the eye
CA2729949A1 (en)	2008-07-08	2010-01-14	Abbott Laboratories	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2303921A2 (en)	2008-07-18	2011-04-06	Centre National de la Recherche Scientifique	Mutated netrin-4 proteins, fragments thereof and their uses as drugs
US8821870B2 (en)	2008-07-18	2014-09-02	Allergan, Inc.	Method for treating atrophic age related macular degeneration
TW201010829A (en)	2008-09-08	2010-03-16	Mobiletron Electronics Co Ltd	Automatic screw feeding apparatus for electricity powered screwdriver
AU2009291747B2 (en)	2008-09-10	2016-05-26	Genentech, Inc.	Methods for inhibiting ocular angiogenesis
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
ES2828721T3 (es)	2008-10-14	2021-05-27	Genentech Inc	Variantes de inmunoglobulina y usos de las mismas
US20120003641A1 (en)	2008-11-05	2012-01-05	Graham Robert R	Genetic polymorphisms in age-related macular degeneration
JP2010117189A (ja)	2008-11-12	2010-05-27	Sumitomo Bakelite Co Ltd	生理活性物質固定化用基板
CA2742786A1 (en)	2008-11-13	2010-05-20	Femta Pharmaceuticals, Inc.	Humanized anti-il-6 antibodies
SI2752189T1 (sl)	2008-11-22	2017-02-28	F. Hoffmann-La Roche Ag	Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
KR101093717B1 (ko)	2008-11-26	2011-12-19	한국생명공학연구원	Ｖｅｇｆ―특이적인 인간항체
KR20110097913A (ko)	2008-12-04	2011-08-31	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
CN102317332B (zh)	2008-12-12	2014-04-30	马萨诸塞大学	两性离子聚合物
EP2379109B1 (en)	2008-12-16	2020-10-07	Bausch Health Companies Inc.	Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
US20100158850A1 (en)	2008-12-23	2010-06-24	The Regents Of The University Of Michigan	Dendrimer based modular platforms
US8349325B2 (en)	2008-12-23	2013-01-08	Abbott Laboratories	Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010085542A2 (en)	2009-01-23	2010-07-29	Novartis Ag	Biomarkers related to age-related macular degeneration (amd)
US8883519B1 (en)	2009-03-17	2014-11-11	University Of Central Florida Research Foundation, Inc.	Oxidase activity of polymeric coated cerium oxide nanoparticles
CN101838329A (zh)	2009-03-18	2010-09-22	嘉和生物药业有限公司	抗血管新生融合蛋白
NZ594343A (en)	2009-03-25	2013-10-25	Genentech Inc	Novel anti-alpha5beta1 antibodies and uses thereof
CN102448984A (zh)	2009-03-27	2012-05-09	酶遗传学股份有限公司	使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
GB0907251D0 (en)	2009-04-28	2009-06-10	Univ Leiden	Coplymers
SG10201402021YA (en)	2009-05-01	2014-10-30	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP3165606A1 (en)	2009-05-01	2017-05-10	Ophthotech Corporation	Methods for treating or preventing ophthalmological diseases
CA2665956A1 (en)	2009-05-07	2010-11-07	Samir Patel	Combination treatment for ocular diseases
TW201422237A (zh)	2009-05-08	2014-06-16	Genentech Inc	人類化之抗-ｅｇｆｌ７抗體及其使用方法
MX2011011925A (es)	2009-05-27	2011-12-06	Hoffmann La Roche	Anticuerpos triespecificos o tetraespecificos.
EP2435075A2 (en)	2009-05-28	2012-04-04	Glaxo Group Limited	Antigen-binding proteins
DK2260873T3 (da)	2009-06-08	2019-09-16	Biocompatibles Uk Ltd	Pcylering af proteiner
TWI510248B (zh) *	2009-06-17	2015-12-01	Abbvie Biotherapeutics Inc	抗－ｖｅｇｆ抗體及其用途
US8703132B2 (en)	2009-06-18	2014-04-22	Hoffmann-La Roche, Inc.	Bispecific, tetravalent antigen binding proteins
RU2012101999A (ru)	2009-06-22	2013-07-27	МЕДИММЬЮН, ЭлЭлСи	РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
US8956600B2 (en) *	2009-08-10	2015-02-17	Taiwan Liposome Co. Ltd.	Ophthalmic drug delivery system containing phospholipid and cholesterol
US20190185555A1 (en)	2017-12-19	2019-06-20	Genentech, Inc.	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
WO2011022264A1 (en)	2009-08-15	2011-02-24	Genentech, Inc.	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
AU2010284433B2 (en)	2009-08-17	2013-12-05	Health Research, Inc.	Combination therapy of cancer with anti-endoglin antibodies and anti-VEGF agents
US20180057602A1 (en)	2009-08-17	2018-03-01	Tracon Pharmaceuticals, Inc.	Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
CN102002104A (zh)	2009-08-28	2011-04-06	江苏先声药物研究有限公司	一种抗vegf的单克隆抗体及含有该抗体的药物组合物
GB0915515D0 (en)	2009-09-04	2009-10-07	Ucl Business Plc	Treatment of vasculoproliferative conditions
WO2011031657A1 (en)	2009-09-08	2011-03-17	Centocor Ortho Biotech Inc.	Use of an anti-il6 antibody to decrease hepcidin in cancer patients
HUE037152T2 (hu)	2009-10-21	2018-08-28	Genentech Inc	Genetikai polimorfizmusok az életkorral összefüggõ makuladegenerációban
EP2493458A2 (en)	2009-10-30	2012-09-05	The Ohio State University	Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
US20110165648A1 (en)	2009-11-04	2011-07-07	Menno Van Lookeren Campagne	Co-crystal structure of factor D and anti-factor D antibody
US20120282211A1 (en) *	2009-11-24	2012-11-08	Carnegie Mellon University	Antibodies and conjugates for modulators of angiogenesis
US8486397B2 (en)	2009-12-11	2013-07-16	Genentech, Inc.	Anti-VEGF-C antibodies and methods using same
WO2011075185A1 (en) *	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
CN103068849B (zh)	2009-12-23	2016-04-06	霍夫曼-拉罗奇有限公司	抗Bv8抗体及其用途
EP2524693B1 (en)	2010-01-14	2014-05-21	Sanwa Kagaku Kenkyusho Co., Ltd	Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
US20110189174A1 (en)	2010-02-01	2011-08-04	Afshin Shafiee	Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
SG183171A1 (en)	2010-02-04	2012-09-27	Agency Science Tech & Res	Use of novel markers of pluripotent stem cells
CN102770450B (zh)	2010-02-16	2015-12-02	诺沃—诺迪斯克有限公司	因子viii融合蛋白
CN105524164A (zh) *	2010-02-16	2016-04-27	诺沃—诺迪斯克有限公司	具有降低的vwf结合的因子viii分子
UA114277C2 (uk)	2010-02-23	2017-05-25	Дженентек, Інк.	Антиангіогенна терапія для лікування раку яєчника
WO2011116387A1 (en)	2010-03-19	2011-09-22	Tetragenetics, Inc.	Production of aglycosylated monoclonal antibodies in ciliates
AR080794A1 (es)	2010-03-26	2012-05-09	Hoffmann La Roche	Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2011119656A1 (en)	2010-03-26	2011-09-29	Genentech, Inc.	Anti-angiogenesis therapy for treating abdominal aortic aneurysm
EP3549963B1 (en)	2010-04-15	2022-01-12	Kodiak Sciences Inc.	High molecular weight zwitterion-containing polymers
EP2560672B1 (en)	2010-04-19	2014-03-05	Research Development Foundation	Rtef-1 variants and uses thereof
WO2011147984A1 (en)	2010-05-28	2011-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
BR112012030600A2 (pt)	2010-07-02	2017-07-11	Genentech Inc	método de tratamento de deslocamento do epitélio pigmentar vascularizado da retina (vped) e de achatamento de um paciente
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
CN102311502B (zh)	2010-07-10	2013-12-25	成都康弘生物科技有限公司	一种抑制血管新生或生长的融合蛋白及其医疗应用
US20120100166A1 (en)	2010-07-15	2012-04-26	Zyngenia, Inc.	Ang-2 Binding Complexes and Uses Thereof
JP2012025820A (ja)	2010-07-21	2012-02-09	Kansai Paint Co Ltd	親水化処理剤組成物
TWI538918B (zh)	2010-10-20	2016-06-21	財團法人工業技術研究院	人源化之單株抗體、其核苷酸序列與其用途
EP2635605B1 (en)	2010-11-01	2018-07-25	Symphogen A/S	Anti-her3 antibodies and compositions
AU2011323521A1 (en)	2010-11-02	2013-06-20	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
US20120263722A1 (en)	2010-11-04	2012-10-18	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
US20120156202A1 (en)	2010-11-05	2012-06-21	Shantha Totada R	Age related macular degeneration treatment
DK2643018T3 (da)	2010-11-23	2021-01-18	Vitaeris Inc	Anti-il-6-antistoffer til behandling af oral mucositis
CN103502464B (zh)	2010-12-02	2016-03-23	神经技术美国有限公司	分泌抗血管生成抗体支架和可溶性受体的细胞系及其用途
CU23895B1 (es)	2010-12-28	2013-05-31	Biorec Sa	Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
KR20200077622A (ko)	2011-01-13	2020-06-30	리제너론 파아마슈티컬스, 인크.	혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP2671589A4 (en)	2011-02-02	2014-11-19	Public Univ Corp Nagoya City Univ	MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
US9125940B2 (en)	2011-02-03	2015-09-08	Zhuning Ma	Compositions and methods for treating macular edema
WO2012123227A1 (en)	2011-02-23	2012-09-20	Sanofi	Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
EP2699256B1 (en)	2011-04-21	2017-09-27	The Regents of the University of Colorado, a body corporate	Compositions and methods for the treatment of neuromyelitis optica
JO3283B1 (ar)	2011-04-26	2018-09-16	Sanofi Sa	تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CA2837169C (en)	2011-05-24	2021-11-09	Zyngenia, Inc.	Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
US10245178B1 (en)	2011-06-07	2019-04-02	Glaukos Corporation	Anterior chamber drug-eluting ocular implant
CN102250246A (zh)	2011-06-10	2011-11-23	常州亚当生物技术有限公司	抗VEGF/PDGFRβ双特异性抗体及其应用
KR101397088B1 (ko)	2011-06-10	2014-05-19	강원대학교산학협력단	암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
EP2726612B1 (en)	2011-06-30	2019-03-06	Gene Signal International SA	Composition comprising inhibitors of irs-1 and of vegf
US20130004511A1 (en)	2011-06-30	2013-01-03	Gene Signal International Sa	Composition comprising inhibitors of irs-1 and of vegf
US9682144B2 (en)	2011-06-30	2017-06-20	Gene Signal International, Sa	Composition comprising inhibitors of IRS-1 and of VEGF
CA2842099A1 (en)	2011-07-27	2013-01-31	Glaxo Group Limited	Antigen binding constructs
BR112014003599A2 (pt)	2011-08-17	2018-04-17	Genentech Inc	método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor
DK2744508T3 (en)	2011-08-19	2018-02-19	Harvard College	VEGF BINING PROTEIN TO BLOCK ANGIOGENESES
US20130071394A1 (en)	2011-09-16	2013-03-21	John K. Troyer	Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
WO2013059137A1 (en) *	2011-10-17	2013-04-25	Oligasis	High molecular weight zwitterion-containing polymers
JO3370B1 (ar)	2011-11-10	2019-03-13	Regeneron Pharma	طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
TWI785403B (zh)	2011-11-14	2022-12-01	安斯泰來再生醫藥協會	人類rpe細胞之醫藥組合物及其用途
US8828401B2 (en)	2011-11-17	2014-09-09	Pfizer Inc.	Cytotoxic peptides and antibody drug conjugates thereof
MX362286B (es)	2011-11-18	2019-01-10	Regeneron Pharma	Microparticulas de polimero y proteina.
WO2013082563A1 (en)	2011-12-01	2013-06-06	Protevobio, Inc.	Protein inhibitors to complement and vegf pathways and methods of use thereof
CN103134874B (zh)	2011-12-01	2015-05-20	成都康弘生物科技有限公司	一种测定蛋白中糖基的方法
MX2014006500A (es)	2011-12-05	2014-08-21	Hoffmann La Roche	Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama.
US20130142796A1 (en)	2011-12-05	2013-06-06	Subhransu Ray	Treatment for angiogenic disorders
ES3027182T3 (en)	2011-12-23	2025-06-13	Pfizer	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
AU2013203424A1 (en)	2012-02-06	2013-08-22	The Regents Of The University Of California	EMP2 regulates angiogenesis in cancer cells through induction of VEGF
JP2015508104A (ja)	2012-02-22	2015-03-16	トラスティーズオブタフツカレッジ	治療薬の眼への送達のための組成物および方法
WO2013134414A1 (en)	2012-03-06	2013-09-12	Galaxy Biotech, Llc	Bispecific antibodies with an fgf2 binding domain
CA2860941C (en)	2012-03-13	2019-11-05	F. Hoffmann-La Roche Ag	Combination therapy for the treatment of ovarian cancer
WO2013152020A1 (en)	2012-04-03	2013-10-10	Novelmed Therapeutics, Inc.	Humanized and chimeric anti-factor bb antibodies and uses thereof
AU2013245630A1 (en)	2012-04-13	2014-10-30	The Johns Hopkins University	Treatment of ischemic retinopathies
HUE046134T2 (hu)	2012-05-07	2020-02-28	Allergan Inc	Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
TWI702955B (zh)	2012-05-15	2020-09-01	澳大利亞商艾佛蘭屈澳洲私營有限公司	使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
JP6234064B2 (ja)	2012-05-23	2017-11-22	キヤノン株式会社	重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法
JP5846044B2 (ja)	2012-05-23	2016-01-20	日油株式会社	（メタ）アクリル酸誘導体の製造方法
EP2855528B1 (en)	2012-05-31	2019-06-19	Genentech, Inc.	Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US20130323242A1 (en)	2012-06-01	2013-12-05	Ophthotech Corp.	Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2013181495A2 (en)	2012-06-01	2013-12-05	Ophthotech Corporation	Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2013181586A2 (en)	2012-06-01	2013-12-05	Momenta Pharmaceuticals, Inc.	Methods related to bevacizumab
SI3679922T1 (sl)	2012-06-01	2021-11-30	Novartis Ag	Brizga
WO2014008292A2 (en)	2012-07-02	2014-01-09	Skyworks Solutions, Inc.	Systems and methods for providing high and low enable modes for controlling radio-frequency amplifiers
JOP20200175A1 (ar)	2012-07-03	2017-06-16	Novartis Ag	حقنة
WO2014006113A1 (en)	2012-07-03	2014-01-09	Sanofi	Method of treating cancer by effective amounts of aflibercept
EP2869846A4 (en) *	2012-07-03	2016-01-13	Janssen Alzheimer Immunotherap	C-TERMINAL AND ANTIBODIES WITH CENTRAL A-BETA EPITOP
RS62509B1 (sr) *	2012-07-13	2021-11-30	Roche Glycart Ag	Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
US20150203591A1 (en)	2012-08-02	2015-07-23	Regeneron Pharmaceuticals, Inc.	Mutivalent antigen-binding proteins
AR091967A1 (es)	2012-08-02	2015-03-11	Sanofi Sa	Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
RU2015104001A (ru)	2012-08-07	2016-09-27	Дженентек, Инк.	Комбинированная терапия для лечения глиобластомы
US11458199B2 (en)	2012-08-21	2022-10-04	Opko Pharmaceuticals, Llc	Liposome formulations
JP6280300B2 (ja)	2012-08-24	2018-02-14	中外製薬株式会社	脳疾患治療剤
EP2890389A1 (en)	2012-08-28	2015-07-08	Novartis AG	Use of a vegf antagonist in treating ocular vascular proliferative diseases
WO2014043480A1 (en)	2012-09-13	2014-03-20	Crystal Ronald G	Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
EP2895489B1 (en)	2012-09-17	2017-10-18	AbbVie Deutschland GmbH & Co. KG	Novel inhibitor compounds of phosphodiesterase type 10a
CA2882463C (en)	2012-09-19	2022-05-03	Genentech, Inc.	Methods and compositions for preventing norleucine misincorporation into proteins
CA2883880A1 (en)	2012-09-28	2014-04-03	Boehringer Ingelheim International Gmbh	Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
DK2906246T3 (da)	2012-10-11	2023-09-04	Ascendis Pharma Ophthalmology Div A/S	VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
EP2906295A4 (en)	2012-10-15	2016-06-01	Oncomed Pharm Inc	METHODS OF TREATING OCULAR DISEASES
EP2906693A1 (en)	2012-10-15	2015-08-19	Novo Nordisk Health Care AG	Coagulation factor vii polypeptides
WO2014066167A1 (en)	2012-10-22	2014-05-01	Fountain Biopharma Inc.	Antibodies to interleukin-6 and uses thereof
SG10201802044RA (en)	2012-11-01	2018-05-30	Abbvie Inc	Stable dual variable domain immunoglobulin protein formulations
KR20180008921A (ko)	2012-11-01	2018-01-24	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
SI2917195T1 (en)	2012-11-05	2018-04-30	Pfizer Inc.	Spliceostatin analogues
EP2916875A1 (en)	2012-11-07	2015-09-16	Pfizer Inc.	Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
KR20210133321A (ko)	2012-11-08	2021-11-05	클리어사이드 바이오메디컬, 인코포레이드	인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
AR093445A1 (es)	2012-11-14	2015-06-10	Regeneron Pharma	Metodos para tratar el cancer de ovario con antagonistas de dll4
CA2892193C (en)	2012-11-21	2018-06-19	Pharmabcine Inc.	Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
AP2015008365A0 (en)	2012-12-05	2015-04-30	Novartis Ag	Compositions and methods for antibodies targeting epo
WO2014099997A1 (en)	2012-12-18	2014-06-26	Novartis Ag	Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014100913A1 (en)	2012-12-24	2014-07-03	Beijing Anxinhuaide Biotech. Co., Ltd	Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
CN103898101B (zh)	2012-12-27	2017-08-08	上海桀蒙生物技术有限公司	利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法
JP2016503817A (ja)	2012-12-31	2016-02-08	ディヴェロップメントセンターフォーバイオテクノロジー	アンチグラニュリシン抗体及びその使用方法
JO3405B1 (ar)	2013-01-09	2019-10-20	Regeneron Pharma	الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014118643A2 (en)	2013-02-04	2014-08-07	Vascular Biogenics Ltd.	Methods of inducing responsiveness to anti-angiogenic agent
CN103193819A (zh)	2013-03-13	2013-07-10	苏州蔻美新材料有限公司	一锅法合成mpc的方法
SI2968461T1 (sl)	2013-03-13	2023-01-31	Genzyme Corporation	Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
US20160015770A1 (en)	2013-03-13	2016-01-21	The Regents Of The University Of Michigan	Compositions for treatment of retinal detachment
RU2015132626A (ru)	2013-03-15	2017-04-25	Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч	Мультимодальные наночастицы на основе диоксида кремния
US20150050277A1 (en)	2013-03-15	2015-02-19	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular diseases
KR102049990B1 (ko)	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9603775B2 (en)	2013-04-24	2017-03-28	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105164157B (zh)	2013-04-29	2024-05-28	豪夫迈·罗氏有限公司	Fc-受体结合的修饰的非对称抗体及使用方法
CA2904806C (en) *	2013-04-29	2021-11-23	F. Hoffmann-La Roche Ag	Human fcrn-binding modified antibodies and methods of use
RU2646098C2 (ru)	2013-04-30	2018-03-01	Интас Фармасьютикалс Лтд	Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
WO2014196658A1 (ja) *	2013-06-06	2014-12-11	学校法人慶應義塾	NMO-IgGに拮抗する抗アクアポリン４抗体
WO2014197849A2 (en)	2013-06-06	2014-12-11	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
EP3010526A1 (en)	2013-06-20	2016-04-27	Novartis AG	Use of a vegf antagonist in treating macular edema
JP2016522248A (ja)	2013-06-20	2016-07-28	ノバルティスアーゲー	ポリープ状脈絡膜血管症の治療
JP2016522249A (ja)	2013-06-20	2016-07-28	ノバルティスアーゲー	脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
CA2917402C (en)	2013-07-09	2019-10-22	Hanwha Chemical Corporation	Novel dual-targeting protein binding specifically to dll4 and vegf and use thereof
CN105377891A (zh)	2013-07-11	2016-03-02	诺华股份有限公司	Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
JP2016523956A (ja)	2013-07-11	2016-08-12	ノバルティスアーゲー	未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
AU2014286996A1 (en)	2013-07-12	2016-01-07	Iveric Bio, Inc.	Methods for treating or preventing ophthalmological conditions
US9252430B2 (en)	2013-07-30	2016-02-02	Spectrum Brands, Inc.	Alkaline cell with improved high rate capability
CN104341504B (zh)	2013-08-06	2017-10-24	百奥泰生物科技(广州)有限公司	双特异性抗体
WO2015023884A2 (en)	2013-08-16	2015-02-19	Board Of Trustees Of Northern Illinois University	Timed release of substances to treat ocular disorders
US20180221483A1 (en)	2013-08-16	2018-08-09	Board Of Trustees Of Northern Illinois University	Timed release of substances to treat ocular disorders
US20150056195A1 (en)	2013-08-23	2015-02-26	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
US10456470B2 (en)	2013-08-30	2019-10-29	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en)	2013-08-30	2020-04-14	Genentech, Inc.	Combination therapy for the treatment of glioblastoma
CN103421039B (zh)	2013-09-03	2015-12-23	重庆工商大学	2-甲基丙烯酰氧基乙基磷酰胆碱的合成方法
ES2819217T3 (es) *	2013-09-08	2021-04-15	Kodiak Sciences Inc	Conjugados de polímeros iónicos dipolares y factor VIII
ES2950987T3 (es)	2013-09-11	2023-10-17	Neurotech Usa Inc	Cartucho para terapia con células encapsuladas
KR102338453B1 (ko)	2013-10-18	2021-12-13	리제너론 파아마슈티컬스, 인크.	Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
WO2015058369A1 (en)	2013-10-23	2015-04-30	Sanofi (China) Investment Co., Ltd.	Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
EP3071181B1 (en)	2013-11-18	2021-03-24	Formycon AG	Pharmaceutical composition of an anti-vegf antibody
US11104730B2 (en)	2013-11-20	2021-08-31	Regeneren Pharmaceuticals, Inc.	Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
BR112016007112A2 (pt)	2013-12-20	2017-09-19	Hoffmann La Roche	Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
CN105263959A (zh)	2013-12-31	2016-01-20	财团法人生物技术开发中心	抗vegf抗体及其用途
US20170002060A1 (en)	2014-01-08	2017-01-05	Moderna Therapeutics, Inc.	Polynucleotides for the in vivo production of antibodies
WO2015109898A1 (zh)	2014-01-24	2015-07-30	上海恒瑞医药有限公司	VEGF与PDGFRβ双特异性融合蛋白及其用途
NZ721607A (en)	2014-01-25	2017-05-26	Chengdu Kanghong Biotechnologies Co Ltd	Fusion protein inhibiting angiogenesis or growth and use thereof
RU2692248C2 (ru)	2014-02-14	2019-06-24	Макродженикс, Инк.	Улучшенные способы лечения васкуляризированных злокачественных опухолей
WO2015132724A1 (en) *	2014-03-05	2015-09-11	Pfizer Inc.	Improved muteins of clotting factor viii
WO2015135583A1 (en)	2014-03-12	2015-09-17	Universität Zu Köln	Method for identifying a candidate subject for anti-vascular endothelial growth factor (vegf) therapy
KR101819135B1 (ko)	2014-03-18	2018-01-18	한국과학기술원	당화 vegf 디코이 수용체 융합 단백질
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US20170143848A1 (en)	2014-03-24	2017-05-25	Shire Human Genetic Therapies, Inc.	Mrna therapy for the treatment of ocular diseases
BR112016022345A2 (pt)	2014-03-31	2017-10-10	Genentech Inc	terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
AU2015243380B2 (en) *	2014-04-11	2020-05-14	Medimmune, Llc	Conjugated compounds comprising cysteine-engineered antibodies
WO2015168321A2 (en)	2014-04-29	2015-11-05	University Of Mississippi Medical Center	Ocular compositions and methods thereof
MA39934A (fr)	2014-05-01	2017-03-08	Hoffmann La Roche	Variants d'anticorps anti-facteur d et leurs utilisations
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3145532A4 (en)	2014-05-02	2018-02-21	Mayo Foundation for Medical Education and Research	Individualized treatment of eye disease
WO2015173260A1 (en)	2014-05-12	2015-11-19	Formycon Ag	Pre-filled plastic syringe containing a vegf antagonist
JP6625064B2 (ja)	2014-05-15	2019-12-25	トランスレイタムメディカスインコーポレイテッド	眼障害を治療かつ診断するための組成物および方法
WO2015195842A1 (en)	2014-06-17	2015-12-23	Clearside Biomedical, Inc.	Methods and devices for treating posterior ocular disorders
EP3160991A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
EP3161000A4 (en)	2014-06-28	2018-05-02	Kodiak Sciences Inc.	Dual pdgf/vegf antagonists
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
CN106460067A (zh)	2014-07-14	2017-02-22	豪夫迈·罗氏有限公司	诊断方法和用于治疗成胶质细胞瘤的组合物
DK3170005T3 (da)	2014-07-18	2019-07-08	Sanofi Sa	Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
CN106573986A (zh)	2014-07-29	2017-04-19	豪夫迈·罗氏有限公司	多特异性抗体
CN106852125A (zh)	2014-08-11	2017-06-13	奥普索特克公司	用于治疗或预防眼科病的方法
MX382673B (es)	2014-09-16	2025-03-13	Regeneron Pharma	Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.
CN105435222B (zh)	2014-09-25	2018-05-29	信达生物制药(苏州)有限公司	重组融合蛋白制剂
WO2016061562A2 (en)	2014-10-17	2016-04-21	Kodiak Sciences Inc.	Butyrylcholinesterase zwitterionic polymer conjugates
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
TWI705827B (zh)	2014-11-07	2020-10-01	瑞士商諾華公司	治療眼部疾病之方法
CN107074941A (zh)	2014-11-10	2017-08-18	豪夫迈·罗氏有限公司	双特异性抗体和用于眼科学的方法
US20160144025A1 (en)	2014-11-25	2016-05-26	Regeneron Pharmaceuticals, Inc.	Methods and formulations for treating vascular eye diseases
ES2907148T3 (es)	2014-12-11	2022-04-22	Bayer Healthcare Llc	Tratamiento de la degeneración macular asociada a la edad con una pequeña lesión de neovascularización coroidea activa
ES2833530T3 (es)	2015-01-06	2021-06-15	Zhuhai Essex Bio Pharmaceutical Co Ltd	Anticuerpo anti-VEGF
US11077093B2 (en)	2015-01-16	2021-08-03	Chugai Seiyaku Kabushiki Kaisha	Combination drug
RU2699544C2 (ru)	2015-01-28	2019-09-06	Пфайзер Инк.	Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
WO2016120307A1 (en)	2015-01-28	2016-08-04	Pieris Ag	Novel proteins specific for angiogenesis
CA2970384A1 (en)	2015-03-11	2016-09-15	Allgenesis Biotherapeutics Inc.	Fusion protein comprising a ligand binding domain of vegf and pdgf
US10421812B2 (en)	2015-03-31	2019-09-24	University Of Massachusetts	Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof
CA2981145C (en)	2015-03-31	2021-05-11	Ildong Pharm Co., Ltd.	Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
AU2016243616A1 (en)	2015-03-31	2017-09-21	Janssen Biotech, Inc	Antigen binding proteins
HK1247217A1 (zh)	2015-04-23	2018-09-21	豪夫迈•罗氏有限公司	结合血管生成素2的抗体与结合编程性死亡配体1的抗体的组合疗法
WO2016170039A1 (en)	2015-04-23	2016-10-27	F. Hoffmann-La Roche Ag	Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide
US10202429B2 (en)	2015-06-08	2019-02-12	Retinal Solutions Llc	Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
US20180221339A1 (en)	2015-06-16	2018-08-09	Translatum Medicus, Inc.	Compositions and methods for treating and diagnosing ocular disorders
WO2017015582A1 (en)	2015-07-22	2017-01-26	Iconic Therapeutics, Inc.	Methods for treating disorders associated with angiogenesis and neovascularization
JP2018525389A (ja)	2015-08-12	2018-09-06	ノバルティスアーゲー	眼障害を治療する方法
WO2017032610A1 (en)	2015-08-21	2017-03-02	F. Hoffmann-La Roche Ag	Affinity chromatography purification with low conductivity wash buffer
RU2727238C2 (ru)	2015-09-01	2020-07-21	Илдонг Фармасьютикал Ко., Лтд.	Фармацевтическая композиция, содержащая в качестве активного ингредиента слитый белок, в котором слиты проникающий в опухоль пептид и антиангиогенное средство, для предупреждения и лечения рака или связанных с ангиогенезом заболеваний
WO2017046140A1 (en)	2015-09-18	2017-03-23	Bayer Pharma Aktiengesellschaft	Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
EP3353203A2 (en)	2015-09-23	2018-08-01	H. Hoffnabb-La Roche Ag	Optimized variants of anti-vegf antibodies
WO2017055539A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Multispecific antibodies
SG10201912150TA (en)	2015-10-06	2020-02-27	Alector Llc	Anti-trem2 antibodies and methods of use thereof
US20170114127A1 (en)	2015-10-22	2017-04-27	Massachusetts Institute Of Technology	Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
JP2018534930A (ja)	2015-10-30	2018-11-29	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体及びコンジュゲート
ES2815224T3 (es)	2015-11-06	2021-03-29	Promise Proteomics	Un método para cuantificar anticuerpos terapéuticos
US20180355030A1 (en)	2015-11-13	2018-12-13	Iconic Therapeutics, Inc.	Methods and compositions for treating disorders associated with pathological neovascularization
MX2018006171A (es)	2015-11-18	2018-12-19	Formycon Ag	Jeringa de plastico precargada que contiene un antagonista de vegf.
WO2017087798A1 (en)	2015-11-18	2017-05-26	Formycon Ag	Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
SG11201803732PA (en)	2015-11-30	2018-06-28	Pieris Australia Pty Ltd	Novel anti-angiogenic fusion polypeptides
DK3384049T3 (da)	2015-12-03	2023-10-02	Regeneron Pharma	Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
ES2925248T3 (es)	2015-12-09	2022-10-14	Univ California	Métodos para tratar una enfermedad o un trastorno oculares
AU2016382786A1 (en)	2015-12-29	2018-07-19	Outlook Therapeutics, Inc.	Buffered formulations of bevacizumab
US11066465B2 (en)	2015-12-30	2021-07-20	Kodiak Sciences Inc.	Antibodies and conjugates thereof
WO2017119435A1 (ja)	2016-01-06	2017-07-13	株式会社オーダーメードメディカルリサーチ	高親和性抗ｖｅｇｆ抗体
US11008387B2 (en)	2016-01-06	2021-05-18	Order-Made Medical Research Inc.	Antibody inhibiting binding of VEGF to NRP1
MX2018008469A (es)	2016-01-08	2018-11-09	Clearside Biomedical Inc	Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.
WO2017120600A1 (en)	2016-01-08	2017-07-13	Clearside Biomedical, Inc.	Compositions and methods of treating wet age-related macular degeneration
WO2017129064A1 (zh)	2016-01-28	2017-08-03	成都康弘生物科技有限公司	抗补体因子D的人源化Fab和人源化抗体及其用途
CU24613B1 (es)	2016-02-06	2022-07-08	Epimab Biotherapeutics Inc	Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr
US20170224815A1 (en)	2016-02-09	2017-08-10	Nima Tirgan	Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
EP3211422A1 (en)	2016-02-23	2017-08-30	Justus-Liebig-Universität Gießen	Method for measurement and control of intraocular vegf concentration
WO2017165681A1 (en)	2016-03-24	2017-09-28	Gensun Biopharma Inc.	Trispecific inhibitors for cancer treatment
KR101975743B1 (ko)	2016-04-07	2019-05-09	한양대학교 에리카산학협력단	신혈관 생성 억제를 위한 혈관내피성장인자 수용체 타겟팅 펩타이드-엘라스틴 융합 폴리펩타이드 및 자가조립 나노구조체
JP2019515904A (ja)	2016-04-14	2019-06-13	アイコニックセラピューティクス，インコーポレイテッド	新血管新生に関連する障害を治療するための組成物および方法
EP3442566A4 (en)	2016-04-14	2019-11-20	Academia Sinica	INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO RECEPTOR, FOR SUPPRESSING THE TUMORANGIOGENESIS
KR20240005973A (ko)	2016-04-15	2024-01-12	리젠엑스바이오 인크.	완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
WO2017180936A1 (en)	2016-04-15	2017-10-19	The Trustees Of The University Of Pennsylvania	Compositions for treatment of wet age-related macular degeneration
US11326182B2 (en)	2016-04-29	2022-05-10	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
US20190142975A1 (en)	2016-04-29	2019-05-16	Adverum Biotechnologies, Inc.	Evasion of neutralizing antibodies by a recombinant adeno-associated virus
CN109310756B (zh)	2016-05-13	2022-06-28	奥美药业有限公司	新型血管生成素2，vegf双特异性拮抗剂
WO2017205559A1 (en)	2016-05-25	2017-11-30	The Johns Hopkins University	Engineered anucleate cellular and extracellular vesicles as a novel biologics delivery platform
RU2765728C2 (ru)	2016-05-25	2022-02-02	Сантен Фармасьютикал Ко., Лтд.	Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком
KR102622823B1 (ko)	2016-06-16	2024-01-10	애드베룸 바이오테크놀로지스, 인코포레이티드	안구 혈관신생을 저하시키기 위한 조성물 및 방법
KR20250107275A (ko)	2016-06-17	2025-07-11	제넨테크, 인크.	다중 특이적 항체의 정제
EP3496752B1 (en)	2016-08-12	2022-05-18	Genentech, Inc.	Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
CA3034701A1 (en)	2016-08-30	2018-03-08	Board Of Regents, The University Of Texas System	Production of seleno-biologics in genomically recoded organisms
EP3509623A4 (en)	2016-09-07	2020-06-03	Saksin Lifesciences PVT Ltd	SYNTHETIC ANTIBODIES TO VEGF AND USES THEREOF
CA3037114A1 (en)	2016-09-19	2018-03-22	Lupin Limited	In-line filter for protein/peptide drug administration
EP3527225A4 (en)	2016-10-12	2020-06-10	Daiichi Sankyo Company, Limited	COMPOSITION WITH ANTI-ROBO4 ANTIBODIES AND OTHER AGENTS
WO2018071767A1 (en)	2016-10-14	2018-04-19	University Of Utah Research Foundation	Antibody-polymer-drug conjugates
US11021530B2 (en)	2016-10-31	2021-06-01	Hexal Ag	Antibody preparation
US11123411B2 (en)	2016-12-08	2021-09-21	Gary E. Borodic	Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
WO2018114728A1 (en)	2016-12-20	2018-06-28	F. Hoffmann-La Roche Ag	Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
WO2018122053A1 (en)	2016-12-29	2018-07-05	F. Hoffmann-La Roche Ag	Anti-angiopoietin-2 antibody formulation
US20190358335A1 (en)	2017-01-12	2019-11-28	Alan J. Russell	Stomach acid-stable and mucin-binding protein-polymer conjugates
CN110545836A (zh)	2017-01-24	2019-12-06	马克雷根有限公司	用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病
EP3573641A4 (en)	2017-01-25	2020-11-11	Iconic Therapeutics, Inc.	TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
KR102252450B1 (ko)	2017-02-09	2021-05-14	주식회사 아미코젠파마	우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2018175319A1 (en)	2017-03-20	2018-09-27	Allergan, Inc.	Heavy chain only antibodies to vegf
UA129242C2 (uk)	2017-03-22	2025-02-26	Дженентек, Інк.	Оптимізована композиція антитіла для лікування захворювань очей
JP7216006B2 (ja)	2017-03-22	2023-01-31	ジェネンテック，インコーポレイテッド	ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
WO2018182527A1 (en)	2017-03-30	2018-10-04	National University Of Singapore	Method for treating inflammatory complications in eye diseases
WO2018185110A1 (en)	2017-04-03	2018-10-11	Fit Biotech Oy	Novel expression vectors and uses thereof
CN106905431B (zh)	2017-04-10	2020-01-17	旭华（上海）生物研发中心有限公司	抗人补体d因子的单克隆抗体及其用途
WO2018191548A2 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
WO2018217995A1 (en)	2017-05-24	2018-11-29	Formycon Ag	Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018218215A1 (en)	2017-05-26	2018-11-29	The Johns Hopkins University	Multifunctional antibody-ligand traps to modulate immune tolerance
WO2019020777A1 (en)	2017-07-26	2019-01-31	Formycon Ag	LIQUID FORMULATION OF A VEGF ANTAGONIST
US10460482B2 (en)	2017-07-26	2019-10-29	Robert Bosch Gmbh	Method and system for automated generation of constrained curves in computer graphics
WO2019040397A1 (en)	2017-08-21	2019-02-28	Ophthotech Corporation	METHOD FOR TREATING OR PREVENTING MACULAR DEGENERATION OF THE NEOVASCULAR AGE
GB201713724D0 (en)	2017-08-25	2017-10-11	Ucl Business Plc	Formulation
WO2019043649A2 (en)	2017-08-31	2019-03-07	Singapore Health Services Pte Ltd	ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES
EP3457139A1 (en)	2017-09-19	2019-03-20	Promise Advanced Proteomics	Antibody-like peptides for quantifying therapeutic antibodies
CN107602702A (zh)	2017-09-22	2018-01-19	生标（上海）医疗器械科技有限公司	一种同时靶向人p185和血管内皮生长因子的抗体及其应用
WO2019057946A1 (en)	2017-09-25	2019-03-28	F. Hoffmann-La Roche Ag	MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
KR20200060456A (ko)	2017-09-27	2020-05-29	리젠엑스바이오 인크.	완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료
AU2018364114B2 (en)	2017-11-08	2024-09-26	Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd.	Conjugates of biomolecule and use thereof
US11596667B2 (en)	2017-11-16	2023-03-07	Iveric Bio, Inc.	Method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
JP7184894B2 (ja)	2017-11-27	2022-12-06	４ディーモレキュラーセラピューティクスインコーポレイテッド	アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
US20200399656A1 (en)	2017-12-05	2020-12-24	University Of Washington	Compositions and methods for enhancing functional expression of therapeutic genes in photoreceptors
CN110003328B (zh)	2018-01-05	2022-04-19	百奥泰生物制药股份有限公司	一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
NZ766484A (en)	2018-01-26	2025-08-29	Univ California	Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN119909169A (zh)	2018-02-06	2025-05-02	豪夫迈·罗氏有限公司	眼科疾病的治疗
CN111712522A (zh)	2018-02-11	2020-09-25	北京韩美药品有限公司	抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019164219A1 (en)	2018-02-20	2019-08-29	Institute For Basic Science	Anti-angiopoietin-2 antibodies and uses thereof
MX2020009152A (es)	2018-03-02	2020-11-09	Kodiak Sciences Inc	Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2019173482A1 (en)	2018-03-06	2019-09-12	Sanford Burnham Prebys Medical Discovery Institute	4-aminoquinoline compounds for the treatment of angiogenesis
TW202003553A (zh)	2018-03-15	2020-01-16	美商艾伯維有限公司	用於治療癌症之abbv-621與抗癌劑之組合
CA3091096A1 (en)	2018-03-16	2019-09-19	Novartis Ag	Methods for treating ocular diseases
WO2019184909A1 (zh)	2018-03-27	2019-10-03	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
WO2019195313A1 (en)	2018-04-04	2019-10-10	Pollack Aryeh L	Anti-vegf antagonist and pedf agonist constructs and uses thereof
WO2019195301A1 (en)	2018-04-05	2019-10-10	Northern Illinois Research Foundation	Hydrogels with liposomes for controlled release of drugs
KR20210009315A (ko)	2018-04-11	2021-01-26	오하이오 스테이트 이노베이션 파운데이션	안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
WO2019201866A1 (en)	2018-04-16	2019-10-24	Swedish Orphan Biovitrum Ab (Publ)	Fusion protein
US20210230261A1 (en)	2018-04-17	2021-07-29	Outlook Therapeutics, Inc.	Buffered formulations of bevacizumab for use of treating diseases
CA3099551C (en)	2018-05-10	2025-08-19	Regeneron Pharma	High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en)	2018-05-25	2022-12-06	Regeneron Pharmaceuticals, Inc.	Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2019229116A1 (en)	2018-05-31	2019-12-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
CA3103374A1 (en)	2018-06-29	2020-01-02	Krystal Biotech, Inc.	Compositions and methods for antibody delivery
EP3813864A4 (en)	2018-06-29	2022-07-20	Gensun Biopharma Inc.	Antitumor antagonists
US11598769B2 (en)	2018-07-27	2023-03-07	Massachusetts Institute Of Technology	Oligomerized protein-polymer conjugates
EP3836959A4 (en)	2018-08-17	2022-05-11	Trican Biotechnology Co., Ltd	ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS
WO2020037225A1 (en)	2018-08-17	2020-02-20	Mersana Therapeutics, Inc.	Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof
CN109053895B (zh)	2018-08-30	2020-06-09	中山康方生物医药有限公司	抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
US10894824B2 (en)	2018-09-24	2021-01-19	Aerpio Pharmaceuticals, Inc.	Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF

2016
- 2016-12-29 US US15/394,500 patent/US11066465B2/en active Active
- 2016-12-29 EP EP16882707.9A patent/EP3397276A4/en active Pending
- 2016-12-29 KR KR1020187021875A patent/KR102799807B1/ko active Active
- 2016-12-29 NZ NZ783685A patent/NZ783685A/en unknown
- 2016-12-29 WO PCT/US2016/069336 patent/WO2017117464A1/en not_active Ceased
- 2016-12-29 SG SG11201805420SA patent/SG11201805420SA/en unknown
- 2016-12-29 IL IL290457A patent/IL290457B2/en unknown
- 2016-12-29 RU RU2018126519A patent/RU2744860C2/ru active
- 2016-12-29 NZ NZ744185A patent/NZ744185A/en unknown
- 2016-12-29 CA CA3010056A patent/CA3010056A1/en active Pending
- 2016-12-29 JP JP2018534732A patent/JP7088454B2/ja active Active
- 2016-12-29 BR BR112018013407A patent/BR112018013407A2/pt active Search and Examination
- 2016-12-29 IL IL260323A patent/IL260323B2/en unknown
- 2016-12-29 KR KR1020257012698A patent/KR20250057128A/ko active Pending
- 2016-12-29 CN CN201680082940.7A patent/CN108712911A/zh active Pending
- 2016-12-29 AU AU2016381964A patent/AU2016381964B2/en active Active
2018
- 2018-06-28 MX MX2022014125A patent/MX2022014125A/es unknown
2021
- 2021-04-08 US US17/301,599 patent/US20210324063A1/en active Pending
- 2021-12-09 JP JP2021199881A patent/JP7414371B2/ja active Active
2023
- 2023-12-26 JP JP2023220012A patent/JP2024038137A/ja active Pending
2024
- 2024-05-01 AU AU2024202872A patent/AU2024202872A1/en active Pending

Also Published As

Publication number	Publication date
EP3397276A4 (en)	2019-12-18
RU2018126519A (ru)	2020-01-30
IL290457B1 (en)	2024-10-01
WO2017117464A1 (en)	2017-07-06
NZ744185A (en)	2025-09-26
IL260323A (en)	2018-08-30
IL260323B1 (en)	2024-09-01
IL290457A (en)	2022-04-01
BR112018013407A2 (pt)	2018-12-18
KR20180104635A (ko)	2018-09-21
AU2016381964B2 (en)	2024-02-15
IL260323B2 (en)	2025-01-01
MX2022014125A (es)	2023-08-08
CN108712911A (zh)	2018-10-26
US20170190766A1 (en)	2017-07-06
JP7088454B2 (ja)	2022-06-21
RU2744860C2 (ru)	2021-03-16
AU2016381964A1 (en)	2018-08-02
KR20250057128A (ko)	2025-04-28
EP3397276A1 (en)	2018-11-07
NZ783685A (en)	2025-09-26
JP7414371B2 (ja)	2024-01-16
KR102799807B1 (ko)	2025-04-24
US20210324063A1 (en)	2021-10-21
AU2024202872A1 (en)	2024-05-23
JP2024038137A (ja)	2024-03-19
JP2022037072A (ja)	2022-03-08
US11066465B2 (en)	2021-07-20
JP2019510734A (ja)	2019-04-18
CA3010056A1 (en)	2017-07-06
IL290457B2 (en)	2025-02-01
SG11201805420SA (en)	2018-07-30

Publication	Publication Date	Title
AU2022228198B1 (ru)	2025-09-11
BE2015C047I2 (ru)	2022-08-10
BE2015C044I2 (ru)	2023-08-31
BR0004687B1 (ru)	2015-05-05
BR0003166B1 (ru)	2015-08-25
BR0000763F1 (ru)	2015-09-15
BR0001536B1 (ru)	2015-09-29
BR0001684B1 (ru)	2015-04-22
BR0001810B1 (ru)	2015-06-23
BR0002033B1 (ru)	2015-06-09
BR0002402B1 (ru)	2015-08-11
BR0002435B1 (ru)	2015-05-19
BR0002694B1 (ru)	2015-08-04
BR0002802B1 (ru)	2015-03-31
BR0002874B1 (ru)	2015-09-01
BR0006634B1 (ru)	2015-06-02
BR0003189B1 (ru)	2015-03-24
BR0003208B1 (ru)	2015-03-17
BR0003401B1 (ru)	2015-08-25
BR0003686B1 (ru)	2015-08-18
BR0008874B1 (ru)	2015-09-15
BR0003751B1 (ru)	2015-08-11
BR0003928B1 (ru)	2015-09-15
BR0009349B1 (ru)	2015-08-18
BR0005041B1 (ru)	2015-08-11